Jefferson Institute of Molecular Medicine and The Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, USA.
Rheumatology (Oxford). 2023 Mar 1;62(3):999-1008. doi: 10.1093/rheumatology/keac451.
SSc is a systemic autoimmune disease of unknown etiology characterized by frequently progressive cutaneous and internal organ fibrosis causing severe disability, organ failure and high mortality. A remarkable feature of SSc is the extension of the fibrotic alterations to nonaffected tissues. The mechanisms involved in the extension of fibrosis have remained elusive. We propose that this process is mediated by exosome microvesicles released from SSc-affected cells that induce an activated profibrotic phenotype in normal or nonaffected cells. Exosomes are secreted microvesicles involved in an intercellular communication system. Exosomes can transfer their macromolecular content to distant target cells and induce paracrine effects in the recipient cells, changing their molecular pathways and gene expression. Confirmation of this hypothesis may identify the molecular mechanisms responsible for extension of the SSc fibrotic process from affected cells to nonaffected cells and may allow the development of novel therapeutic approaches for the disease.
系统性硬化症(SSc)是一种病因不明的系统性自身免疫性疾病,其特征为频繁进行性皮肤和内脏器官纤维化,导致严重残疾、器官衰竭和高死亡率。SSc 的一个显著特征是纤维化改变延伸至未受影响的组织。涉及纤维化延伸的机制仍不清楚。我们提出,该过程由 SSc 受影响细胞释放的外泌体微囊泡介导,这些微囊泡诱导正常或未受影响细胞中激活的致纤维化表型。外泌体是参与细胞间通讯系统的分泌微囊泡。外泌体可以将其大分子内容物转移到远处的靶细胞,并在受体细胞中诱导旁分泌效应,改变其分子途径和基因表达。该假说的证实可能确定导致 SSc 纤维化过程从受影响细胞扩展到未受影响细胞的分子机制,并可能为该疾病开发新的治疗方法。